

Form PTO-1449 (Modified)

U. S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29853/37702Serial No.
10/033,571

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Zhang, et al.Filing Date
12/27/01Group
1648

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
MM ↓	4,352,883	10/05/82	Lim	435	178	
	4,725,547	02/16/88	Sakamoto, et al.	435	239	
	5,607,851	03/04/97	Pellegrini, et al.	435	236	
	* 5,744,304	04/28/98	Munford	436	6	
	* 5,837,520	11/17/98	Shabram, et al.	435	239	

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation
MM ↓	* 4 9338	01/14/92	JAPAN			
	* 0 475 623 A1	03/18/92	EPO			
	* WO 93/25224	12/23/93	PCT			
	* WO 94/06910	03/31/94	PCT			
	WO 94/17178	08/04/94	PCT			
	WO 95/25789	08/28/95	PCT			
	WO 96/27677	09/12/96	PCT			
	* WO 97/04803	02/13/97	PCT			
	WO 97/08298	03/06/97	PCT			
	WO 98/00524	01/08/98	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MM ↓	Aboud, et al., "Rapid purification of extracellular and intracellular moloney murine leukemia virus," <i>Arch. Virol.</i> , 71:185-195, 1982.
	Berg, et al., "High-live expression of secreted proteins from cells adapted to serum-free suspension culture," <i>BioTechniques</i> , 14(6):972-978, 1993.
	Bett, "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3," <i>Proc. Natl. Acad. Sci. USA</i> , 91(19):8802-8806, 1994.

EXAMINER.

Wesley

DATE

10-18-04

Form PTO-1449 (Modified)

JUN 03 2002

U.S. Department of Commerce
Patent and Trademark OfficeApp. Docket No.
29853/37702Serial No.
10/033,571

INFORMATION DISCLOSURE STATEMENT

Applicant
Zhang, et al.Filing Date
12/27/01Group
1648

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MM	*	Cartwright, Terrance, "Animal cells as bioreactors," Cambridge University Press, pp. 58-63, 1994
	*	Complaint Aventis Pharmaceuticals Products, Inc. and Aventis Pharma, S.A., Plaintiffs, v. Introgen Therapeutics, Inc., Defendant. Civil Action No. 01-451 from the U.S. District Court for the District of Delaware, June 29, 2001, dismissed with prejudice July 2, 2001.
		Crooks, et al., "Purification and analysis of infectious virions and native non-structural antigens from cells infected with tick-borne encephalitis virus," <i>J. Chrom.</i> , 502:59-68, 1990.
		Garnier, et al., "Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells," <i>Cytotechnol.</i> , 15:145-155, 1994.
		Gilbert, "Adaptation of cells to serum-free culture for production of adenovirus vectors and recombinant proteins," <i>Williamsburg BioProcessing Conference</i> , Nov. 18-21, 1996.
		Graham and Prevec, "Manipulation of adenovirus vectors," <i>Int. Methods in Molecular Biology: Gene Transfer and Expression Protocols 7</i> , (Murray, Ed.) Humana Press, Clifton, NJ, pp. 109-128, 1991.
		Graham, et al., "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," <i>J. Gen. Virol.</i> , 36:59-72, 1977.
		Graham, "Growth of 293 Cells in Suspension Culture," <i>J. Gen. Virol.</i> , 68:937-940, 1987.
		Griffiths, "Overview of cell culture systems and their scale-up," <i>In: Animal Cell Biotechnology</i> , 3:179-220, 1986.
		Hay, et al., "Replication of adenovirus mini-chromosomes," <i>J. Mol. Biol.</i> , 175:493-510, 1984.
		Hearing and Shenk, "Functional analysis of the nucleotide sequence surrounding the cap site for adenovirus type 5 region E1A messenger RNAs," <i>J. Mol. Biol.</i> , 167:809-822, 1983.
		Hearing, et al., "Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome," <i>J. Virol.</i> , 61:2555-2558, 1987.
		Huyghe, et al., "Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography," <i>Hum. Gene Ther.</i> , 6:1403-1416, 1996.
		International Search Report dated July 16, 1998 (PCT/US97/21504) (INON-058P).
MM		Jones and Shenk, "Isolation of deletion and substitution mutants of adenovirus type 5," <i>Cell</i> , 13:181-188, 1978.
		Larsson and Litwin, "The growth of polio virus in human diploid fibroblasts grown with cellulose microcarriers in suspension cultures," <i>Dev. Bio. Standard</i> , 66:385-390, 1987.

EXAMINER:

Wishy

DATE:

10-18-04

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

29853/37702

Serial No.

10/033,571

Applicant

Zhang, et al.

Filing Date

12/27/01

Group

1648

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MM		Lentfer, D. and Conde, C., "A Rapid and Inexpensive Procedure for the Purification of Adenovirions" 1978.
		Levrero, et al., "Defective and nondefective adenovirus vectors for expressing foreign genes <i>in vitro</i> and <i>in vivo</i> ," <i>Gene</i> , 101:195-202, 1991.
		Mann, et al., "Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus," <i>Cell</i> , 33:153-159, 1983.
		McGrath, et al., "Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity" <i>J. Virol.</i> , 25:923-927, 1978.
		Mizrahi, "Production of human interferons-an overview," <i>Proc. Biochem.</i> , (August):9-12, 1983.
		Montagnon, B.J., "Polio and Rabies Vaccines Produced in Continuous Cell Lines: A Reality for Vero Cell Line" 1989.
		Morris, et al., "Serum-free production of adenoviral vectors for gene therapy," <i>Williamsburg BioProcessing Conference</i> , Nov. 18-21, 1996.
	*	Nadeau, et al., "Improvement of Recombinant Protein Production with the Human Adenovirus/293S Expression System Using Fed-Batch Strategies," <i>Biotechnology and Bioengineering</i> 51:613-23, 1996.
		Nicolas and Rubenstein, "Vectors: a survey of molecular cloning vectors and their uses," <i>In: Vectors: A survey of molecular cloning vectors and their uses</i> , (Rodriguez and Behhardt, eds.), Stoneham: Butterworth, pp. 493-513, 1988.
		Nilsson and Mosbach, "Immobilized animal cells," <i>Dev. Biol. Standard</i> , 66:183-193.
		O'Neil and Balkovic, "Virus harvesting and affinity-based liquid chromatography," <i>Bio. Technol.</i> , 11:173-178, 1993.
	*	Payment, et al., in <i>Biotechnology Current Progress</i> , Eds. Paul Cheremisinoff and Louise Ferrante, Technomic Publishing Co., Lancaster/Basel, Vol. 1, pp. 61-82, 1991.
		Perrin, et al. "An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process; use of serum-free medium and perfusion-reactor system," <i>Vaccine</i> , 13(13):1244-1250, 1995.
		Petricciani, "Should continuous cell lines be used as substrates for biological products?," <i>Dev. Biol. Standard</i> , 66:3-13, 1985.
		Phillips, et al., "Experience in the cultivation of mammalian cells on the 8000 l scale," <i>In: Large Scale Mammalian Cell Culture</i> (Feder and Tolbert, eds.), Academic Press, Orlando, FL, U.S.A., 1985.
✓		Provisional U.S. Patent Application Serial No. 60/026,667. Entitled: "METHOD FOR THE PRODUCTION OF RECOMBINANT ADENOVIRUSES," RPR File No. ST96021-U.S., Translated from the French by the Medical Documentation Service® Institute for Scientific Information® Philadelphia, Pennsylvania.

EXAMINER

Mokky

DATE

10-18-04

Form PTO-1449 (Modified)

U. S. Department of Commerce
Patent and Trademark Office

Any Docket No.

29853/37702

Serial No.

10/033,571

Applicant

Zhang, et al.

Filing Date

12/27/01

Group

1648

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MM	Roux, et al., "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses," <i>Proc. Nat'l Acad. Sci. USA</i> , 86:9079-9083, 1989.
	Smith and Lee, "Large-scale isolation and partial purification of type C RNA viruses on hydroxyapatite," <i>Analytical Biochem.</i> , 86:252-263, 1978.
	Temin, "Retrovirus vectors for gene transfer: efficient integration into and expression of exogenous DNA in vertebrate cell genomes," <i>In: Gene Transfer</i> , (Kucherlapati, ed.) Plenum Press, New York, pp. 149-188, 1986.
	Tibbetts, "Viral DNA sequences from incomplete particles of human adenovirus type 7," <i>Cell</i> , 12:243-249, 1977.
	* Trepanier, et al., "Concentration of Human Respiratory Syncytial Virus Using Ammonium Sulfate, Polyethylene Glycol or Hollow Fiber Ultrafiltration," <i>Journal of Virological Methods</i> 3:201-211, 1981.
	van Wezel, "Growth of cell-strains and primary cells on micro-carriers in homogeneous culture," <i>Nature</i> , 216:64-65, 1967.
	Wang, et al., "High cell density perfusion culture of hybridoma cells for production of monoclonal antibodies in the celligen packed bed reactor," <i>In: Animal Cell Technology: Basic & Applied Aspects</i> , (Kaminogawa, et al., eds), Kluwer Academic Publishers, Netherlands, 5:463-469, 1993.
	Wang, et al., "Modified CelliGen-packed bed bioreactors for hybridoma cell cultures," <i>Cytotechnol.</i> , 9:41-49, 1992.
W	* Wills, et al., "Adenovirus Vectors of Gene Therapy of Cancer," <i>Journal of Cellular Biochemistry</i> , Supp. 17E, S216:206, 1993.

EXAMINER:

Moly

DATE:

10-18-04



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/033,571-Conf. #09714	
			Filing Date	December 27, 2001	
			First Named Inventor	Shuyuan Zhang	
			Art Unit	1648	
			Examiner Name	M. Mosher	
Sheet	1	of	1	Attorney Docket Number	29853/37702

RECEIVED
SEP 17 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
M/M	A	US-6,485,958 B2	11/26/02	Blanche et al.	
	B	US-6,537,793B2	03/25/03	Blanche, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Mosher</i>	Date Considered	10-18-04
-----------------------	---------------	--------------------	----------